Sebia

Founded in 1967, Sebia is a world-leading provider of clinical protein electrophoresis equipment and reagents, a technology used for in-vitro diagnostic testing.

Its systems analyse proteins in order to screen and monitor various diseases and conditions; primarily oncology (Multiple Myeloma), metabolic disorders such as Diabetes and also Hemoglobinopathy and rare pathologies. The company is headquartered in Lisses, France, and operates across more than 120 countries. 

"Our new shareholders support our strategy and growth plans with a long term view. We look forward to reinforcing Sebia's franchise and expand its product and geographical footprint."

Dr Benoît Adelus, Vorsitzender

Investitionszeitpunkt

February 2018

Fund

CVC Strategic Opportunities

Geschäftsfeld

Diagnostic equipment and reagents

Niederlassung

France

Vorsitzender

Dr Benoît Adelus

Webseite

sebia.com